Dr. Paul Micevych from the UC San Francisco discusses his group's work on systemic and individual risk factors leading to complicated diabetic retinopathy requiring vitrectomy. 

Discussed article: Micevych PS, Taha AM, Poddar A, Stewart JM. Individual and Systems-Based Risk Factors for Diabetic Vitrectomy in an Urban Safety-Net Hospital. Ophthalmol Retina. 2023 Dec;7(12):1027-1034. doi: 10.1016/j.oret.2023.05.014. Epub 2023 May 24. PMID: 37236319.

Dr. Nina Ahuja and Dr. Nupura Bakshi elaborate on the concept of Equity, Diversity and Inclusion in medicine and discuss their recent publication about the EDI landscape in the Canadian ophthalmology post-secondary programs. The discussed article:

Lee EY, Farrokhyar F, Bakshi N, Levin LA, Ahuja N. Equity, diversity, and inclusion landscape in Canadian postgraduate medical education for ophthalmology. Can J Ophthalmol. 2024 Feb;59(1):31-39. doi: 10.1016/j.jcjo.2022.08.015. Epub 2022 Sep 24. PMID: 36162441.

Dr. Sarraf talks about his group's work on the correlation of PED size and variablity and the visual improvement during the treatment of neovascular AMD as analyzed using data from HAWK and HARRIER studies.

Referenced article:  Sarraf D, Khanani AM, Sadda SR, Chang A, Wong DT, Kempf AS, Saffar I, Tang S, Tadayoni R. PIGMENT EPITHELIAL DETACHMENT THICKNESS AND VARIABILITY AFFECTS VISUAL OUTCOMES IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2024 Jan 1;44(1):10-19. doi: 10.1097/IAE.0000000000003935. PMID: 37824807.

Dr. Jong Park discusses surgical mananement of full-thickness macular holes associated with macular telangiectasia. 

Referenced article:

Park JG, Adrean SD, Begaj T, Capone A Jr, Charles S, Chen SN, Chou HD, Cohen MN, Corona ST, Faia LJ, Garg SJ, Garretson BR, Gregori NZ, Haller JA, Houghton OM, Hsu J, Jo J, Kaiser RS, Lai CC, Mahgoub MM, Mansoor M, Matoba R, Morizane Y, Nehemy MB, Raphaelian PV, Regillo CD, Ruby AJ, Runner MM, Sneed SR, Sohn EH, Spirn MJ, Vander JF, Wakabayashi T, Wolfe JD, Wykoff CC, Yonekawa Y, Yoon YH, Mahmoud TH. Surgical Management of Full-Thickness Macular Holes in Macular Telangiectasia Type 2: A Global Multicenter Study. Ophthalmology. 2024 Jan;131(1):66-77. doi: 10.1016/j.ophtha.2023.08.025. Epub 2023 Sep 3. PMID: 37661066.

Dr. Landon Rohowetz discusses his group's findings of a retrospective analysis of the characteristics of Retinal Detachment cases that were associated with Retinal Dialysis. 

Discussed article:

Rohowetz LJ, Jabbehdari S, Smiddy WE, Berrocal AM, Townsend JH, Chang JS, Yannuzzi N, Sridhar J, Haddock LJ, Fortun JA, Flynn HW Jr; Retinal Dialysis Study Group. Retinal Detachment Associated with Retinal Dialysis: Clinical Features and Outcomes of Surgery in a 10-Year Study. Ophthalmol Retina. 2023 Oct;7(10):857-861. doi: 10.1016/j.oret.2023.06.013. Epub 2023 Jun 26. PMID: 37379884; PMCID: PMC10592222.

Dr. Jabs and Dr. Acharya discuss the results of the MERIT trial that investigated relative efficacy of intrvitreal injections of Dexamethasone implant vs ranibizumab vs methotrexate for the treatment of macular oedema associated with uveitis. Discussed article:

Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee:; Acharya NR, Vitale AT, Sugar EA, Holbrook JT, Burke AE, Thorne JE, Altaweel MM, Kempen JH, Jabs DA. Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results. Ophthalmology. 2023 Sep;130(9):914-923. doi: 10.1016/j.ophtha.2023.04.011. Epub 2023 Jun 13. PMID: 37318415; PMCID: PMC10524707.

Prof. Gemmy Cheung from the National University of Singapore and Singapore National Eye Center discusses her research results on progression of Geographic Atrophy on Asian vs non-Asian Eyes.

References Article:

Teo KYC, Fujimoto S, Sadda SR, Kokame G, Gomi F, Kim JE, Cheng MFS, Corradetti G, Amornpetchsathaporn A, Chainakul M, Lee WK, Lai TYY, Ruamviboonsuk P, Cheung CMG. Geographic Atrophy Phenotypes in Subjects of Different Ethnicity: Asia-Pacific Ocular Imaging Society Work Group Report 3. Ophthalmol Retina. 2023 Jul;7(7):593-604. doi: 10.1016/j.oret.2022.12.013. Epub 2022 Dec 28. PMID: 36586466.

Dr. Regillo describes the results of the phase 3 prospective study of Ranibizumab Port Delivery System (PDS) for the treatment of neovascular AMD. 

Reference Article:

Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024. Epub 2023 Mar 2. PMID: 36870451.

Dr. Smiddy presents a cost analysis of the step therapy for treatment of diabetic macular edema based on DRCR protocol AC results.

Discussed article:

Patel NA, Al-Khersan H, Yannuzzi NA, Lin J, Smiddy WE. Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results. Ophthalmol Retina. 2023 May;7(5):413-419. doi: 10.1016/j.oret.2022.11.010. Epub 2022 Nov 22. PMID: 36423893.

Dr. Jason Hsu from Wills Eye Hospital returns to The Retina Channel to discuss his groups' retrospective study of eyes with advanced retinal detachement (PVR grade C or worse) that underwent retinectomy without lensectomy. Their study showed that 75% of these eyes at 3 months (and 68% at 6 months) had single surgery anatomic success. The study is suggestive that lensectomy and even peripheral vitreous base sheving may not be necessary when doing retinectomy for advanced RD cases. 

Full reference to the article:

Mahmoudzadeh R, Mokhashi N, Anderson H, Patel S, Salabati M, Chiang A, Kuriyan AE, Gupta OP, Mehta S, Garg SJ, Hsu J. Outcomes of Retinectomy without Lensectomy in Rhegmatogenous Retinal Detachments with Proliferative Vitreoretinopathy. Ophthalmol Retina. 2023 Jan;7(1):52-58. doi: 10.1016/j.oret.2022.07.008. Epub 2022 Aug 5. PMID: 35940476.

Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD.